Replies to post #420319 on Anavex Life Sciences Corp (AVXL)

[raja48185]

And while you're trying to explain why Novocure is going to be "obsolete", please explain what happened to SRPT's share price?

3.2 Million Dollar Gene therapy per patient says it all. Initial market reaction is based on price shock and questions about reimbursement.

Some of the issues highlighted in article below.


https://www.investors.com/news/technology/srpt-stock-halted-sarepta-wins-fda-approval-for-duchenne-gene-therapy/?src=A00220